AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29078170 — intervention group
Group type: COMPARATOR
Intervention: Non-Type D personality
Number of subjects: 570
Study 29078273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (anti-VEGF drug)
Number of subjects: 0
Study 29078273 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking EPO function (pharmacological approach)
Number of subjects: 0
Study 29078273 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic loss-of-function (deletion of EpoR in nonerythroid cells)
Number of subjects: 0
Study 29078755 — intervention group
Group type: EXPERIMENTAL
Intervention: NPI-NH
Number of subjects: 83
Study 29078755 — intervention group
Group type: EXPERIMENTAL
Intervention: CSDD
Number of subjects: 83
Study 29078755 — intervention group
Group type: COMPARATOR
Intervention: Actigraphy
Number of subjects: 83
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-malarial treatment
Number of subjects: 6401
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed net use
Number of subjects: 6401
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopy assessment of PfPR
Number of subjects: 6401
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: PfPR over 3 years
Number of subjects: 6401
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: PfPR by age group
Number of subjects: 6401
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever and anaemia
Number of subjects: 6401
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: Local PfPR variation
Number of subjects: 6401
Study 29078773 — intervention group
Group type: EXPERIMENTAL
Intervention: Children 6 months-4 years
Number of subjects: 6401
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with endometriosis (WwE)
Number of subjects: 268
Study 29079275 — intervention group
Group type: COMPARATOR
Intervention: Control women (CW)
Number of subjects: 268
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfertile WwE
Number of subjects: 268
Study 29079275 — intervention group
Group type: COMPARATOR
Intervention: Subfertile CW
Number of subjects: 268
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertile WwE
Number of subjects: 268
Study 29079275 — intervention group
Group type: COMPARATOR
Intervention: Fertile CW
Number of subjects: 268
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: WwE with rASRM I/II
Number of subjects: 268
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: WwE with rASRM III/IV
Number of subjects: 268
Study 29079275 — intervention group
Group type: COMPARATOR
Intervention: CW
Number of subjects: 268
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: WwE with superficial peritoneal endometriosis
Number of subjects: 268
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: WwE with ovarian endometriosis
Number of subjects: 268
Study 29079275 — intervention group
Group type: EXPERIMENTAL
Intervention: WwE with deep infiltrating endometriosis
Number of subjects: 268
Study 29079496 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 95
Study 29079496 — intervention group
Group type: COMPARATOR
Intervention: Renal mass biopsy (RMB)
Number of subjects: 95
Study 29079551 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (tailored physical training for 3-6 weeks before surgery)
Number of subjects: 56
Study 29079551 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard ERAS pathway without prehabilitation)
Number of subjects: 56
Study 29079600 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide (Xagrid)
Number of subjects: 3649
Study 29079600 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3649
Study 29079633 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe persistent hyponatraemia (serum sodium <130 mmol/L)
Number of subjects: 116
Study 29079633 — intervention group
Group type: COMPARATOR
Intervention: Control group (without severe persistent hyponatraemia)
Number of subjects: 116
Study 29079633 — intervention group
Group type: EXPERIMENTAL
Intervention: RV dysfunction
Number of subjects: 116
Study 29079633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatraemia
Number of subjects: 116
Study 29079658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) measurements using Abbott assay, sex-specific 99th percentiles (women, 16 ng/L; men, 34 ng/L)
Number of subjects: 1555
Study 29079658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) measurements
Number of subjects: 1555
Study 29079987 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel DGP treatment (specifics not provided)
Number of subjects: 90
Study 29080061 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CTh+)
Number of subjects: 362
Study 29080061 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 362
Study 29080061 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 362
Study 29080061 — intervention group
Group type: EXPERIMENTAL
Intervention: CTh+
Number of subjects: 362
Study 29080065 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT) for 5 weeks
Number of subjects: 9
Study 29080864 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial cardiac catheterization
Number of subjects: 50
Study 29080915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 25
Study 29080915 — intervention group
Group type: COMPARATOR
Intervention: 8 mg triamcinolone
Number of subjects: 25
Study 29080970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg
Number of subjects: 20
Study 29080970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 1680 mg
Number of subjects: 20
Study 29080970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29080970 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 20
Study 29081368 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV (single dose)
Number of subjects: 250
Study 29081664 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 10 mg/day
Number of subjects: 302
Study 29081664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302
Study 29081977 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3234
Study 29081977 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin therapy)
Number of subjects: 3234
Study 29082335 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 12-lead ECG once daily for 5 days
Number of subjects: 1200
Study 29082335 — intervention group
Group type: COMPARATOR
Intervention: 24-h Holter monitoring
Number of subjects: 1200
Study 29082650 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine therapy throughout pregnancy
Number of subjects: 0
Study 29082856 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection in T2DM patients
Number of subjects: 797
Study 29082856 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 797
Study 29083031 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 0
Study 29083031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 29083031 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy techniques
Number of subjects: 0
Study 29083031 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Training (IBT)
Number of subjects: 0
Study 29083050 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 73
Study 29083050 — intervention group
Group type: EXPERIMENTAL
Intervention: R-cytarabine
Number of subjects: 73
Study 29083050 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP and R-cytarabine alternating regimen
Number of subjects: 73
Study 29084559 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepex circumcision
Number of subjects: 304
Study 29084708 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Up mobile phone app
Number of subjects: 60
Study 29084708 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews and focus groups with 30 young people, parents, and clinicians
Number of subjects: 60
Study 29084797 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing in UK GP
Number of subjects: 1000
Study 29084797 — intervention group
Group type: COMPARATOR
Intervention: PSA level ≥3 in UK GP
Number of subjects: 1000
Study 29084869 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous immunoglobulin treatment
Number of subjects: 0
Study 29085669 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 0
Study 29085669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 29085669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29085815 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident training programs (talks, day camps, thematic activities) in the intervention group.
Number of subjects: 0
Study 29085815 — intervention group
Group type: COMPARATOR
Intervention: Control group with no program implemented.
Number of subjects: 0
Study 29086340 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster patients without post-herpetic neuralgia (PHN)
Number of subjects: 412
Study 29086340 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster patients with post-herpetic neuralgia (PHN)
Number of subjects: 412
Study 29086392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydralazine and isosorbide dinitrate (Hy+ISDN)
Number of subjects: 0
Study 29086499 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (PA) by 160% ± 23%
Number of subjects: 14
Study 29086499 — intervention group
Group type: COMPARATOR
Intervention: Increased physical activity (PA) by 34% ± 25%
Number of subjects: 14
Study 29086499 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake (EI) changes of -8.7% ± 5.6%
Number of subjects: 14
Study 29086499 — intervention group
Group type: COMPARATOR
Intervention: Energy intake (EI) changes of -7.4% ± 2.7%
Number of subjects: 14
Study 29086499 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PA
Number of subjects: 14
Study 29086499 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in EI
Number of subjects: 14
Study 29086504 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + AT
Number of subjects: 249
Study 29086504 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + RT
Number of subjects: 249
Study 29086504 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 249
Study 29086529 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss attempts
Number of subjects: 3008
Study 29086529 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of obesity as a disease
Number of subjects: 3008
Study 29086529 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about weight affecting future health
Number of subjects: 3008
Study 29086529 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility for weight loss
Number of subjects: 3008
Study 29086529 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identification as obese
Number of subjects: 3008
Study 29086529 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled follow-up for weight-related conversations
Number of subjects: 3008
Study 29086529 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of employer-sponsored wellness offerings
Number of subjects: 3008
Study 29086923 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT/A)
Number of subjects: 0
Study 29087448 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission functional decline
Number of subjects: 2011
Study 29087448 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe cognitive impairment
Number of subjects: 2011
Study 29087448 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 2011
Study 29087448 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2011
Study 29087448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing impairment
Number of subjects: 2011
Study 29087448 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment
Number of subjects: 2011
Study 29087741 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term supplemental oxygen treatment
Number of subjects: 34
Study 29087741 — intervention group
Group type: COMPARATOR
Intervention: Control (no long-term supplemental oxygen)
Number of subjects: 34
Study 29089191 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent live attenuated influenza vaccine (LAIV4) or inactivated influenza vaccine (IIV4)
Number of subjects: 266
Study 29089191 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging for reporting symptoms
Number of subjects: 266
Study 29089191 — intervention group
Group type: COMPARATOR
Intervention: Text messaging versus paper reporting
Number of subjects: 266
Study 29089314 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus-eluting Absorb BVS (n=2164)
Number of subjects: 3389
Study 29089314 — intervention group
Group type: COMPARATOR
Intervention: cobalt-chromium everolimus-eluting stents (n=1225)
Number of subjects: 3389
Study 29089744 — intervention group
Group type: EXPERIMENTAL
Intervention: Rohto Dry-Aid
Number of subjects: 0
Study 29089744 — intervention group
Group type: COMPARATOR
Intervention: Systane Ultra
Number of subjects: 0
Study 29090343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 3525
Study 29090343 — intervention group
Group type: COMPARATOR
Intervention: Non-intensive treatment or best supportive care
Number of subjects: 3525
Study 29090343 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific AML incidence rates
Number of subjects: 3525
Study 29090343 — intervention group
Group type: EXPERIMENTAL
Intervention: ELN risk categorization
Number of subjects: 3525
Study 29090343 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG performance status < 2
Number of subjects: 3525
Study 29090343 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT-CI comorbidity index < 3
Number of subjects: 3525
Study 29090343 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating FLT3 mutations
Number of subjects: 3525
Study 29090520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 730
Study 29090520 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic patients
Number of subjects: 730
Study 29091557 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of adeno-associated virus serotype 9 carrying SMN complementary DNA
Number of subjects: 15
Study 29091557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cohort of adeno-associated virus serotype 9
Number of subjects: 15
Study 29092017 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical correction of pectus carinatum (PC)
Number of subjects: 6
Study 29092017 — intervention group
Group type: COMPARATOR
Intervention: Conservative compression treatment
Number of subjects: 6
Study 29092051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained obesity (cumulative excess BMI ≥5 kg/m2) in men age >35 years and women age <35 years
Number of subjects: 665
Study 29092051 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >35 years
Number of subjects: 665
Study 29092051 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 665
Study 29092051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative excess BMI (ceBMI) values ≥0 kg/m2 and ≥5 kg/m2
Number of subjects: 665
Study 29092051 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 665
Study 29092792 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe postoperative complications
Number of subjects: 137
Study 29092792 — intervention group
Group type: COMPARATOR
Intervention: Patients without severe postoperative complications
Number of subjects: 137
Study 29092845 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 84
Study 29092845 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 84
Study 29092845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome
Number of subjects: 84
Study 29092878 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soluble fiber supplementation
Number of subjects: 0
Study 29092878 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29092957 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic and transcriptomic profiling of liver metastases from PNET patients.
Number of subjects: 5
Study 29093707 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on Pyridostigmine (PDG)
Number of subjects: 7
Study 29093819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) adapted for Adolescents
Number of subjects: 39
Study 29093819 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 39
Study 29093819 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-syndrome BPD
Number of subjects: 39
Study 29093819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-threshold BPD
Number of subjects: 39
Study 29093819 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (DBT and enhanced usual care)
Number of subjects: 39
Study 29093819 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with BPD
Number of subjects: 39
Study 29093819 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline level of clinician-rated depressive symptoms
Number of subjects: 39
Study 29094043 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted passive hand mobilization for 20 minutes
Number of subjects: 23
Study 29094152 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire Overall Summary scores (KCCQ-os)
Number of subjects: 3041
Study 29094152 — intervention group
Group type: EXPERIMENTAL
Intervention: Current KCCQ-os scores
Number of subjects: 3041
Study 29094152 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in KCCQ-os scores
Number of subjects: 3041
Study 29094152 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 3041
Study 29095433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild neonatal encephalopathy (NE) infants
Number of subjects: 63
Study 29095433 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study 29095677 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 504
Study 29095677 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FM (rituximab plus fludarabine and mitoxantrone)
Number of subjects: 504
Study 29095677 — intervention group
Group type: COMPARATOR
Intervention: R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone)
Number of subjects: 504
Study 29095678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for up to 24 months
Number of subjects: 24
Study 29095970 — intervention group
Group type: EXPERIMENTAL
Intervention: Step reduction (SR; <1,000 steps.d-1 for 14 d)
Number of subjects: 22
Study 29095970 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery (RC) after step reduction
Number of subjects: 22
Study 29095970 — intervention group
Group type: EXPERIMENTAL
Intervention: Step reduction (SR)
Number of subjects: 22
Study 29095983 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily) for 9.4 to 13.7 weeks
Number of subjects: 10
Study 29096229 — intervention group
Group type: EXPERIMENTAL
Intervention: L3 skeletal muscle index (L3SMI)
Number of subjects: 231
Study 29096647 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV knowledge assessment for patients
Number of subjects: 240
Study 29096647 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV knowledge assessment for staff
Number of subjects: 240
Study 29096647 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to HCV medical treatment for HCV-positive patients
Number of subjects: 240
Study 29096647 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to HCV-related services
Number of subjects: 240
Study 29096668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy
Number of subjects: 58
Study 29096668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 58
Study 29096668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus other treatment
Number of subjects: 58
Study 29096668 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate to lenalidomide-based therapy
Number of subjects: 58
Study 29096668 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events after lenalidomide-containing therapy
Number of subjects: 58
Study 29096668 — intervention group
Group type: EXPERIMENTAL
Intervention: Median duration of response
Number of subjects: 58
Study 29096670 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF plus darunavir 800 mg daily
Number of subjects: 10
Study 29096697 — intervention group
Group type: EXPERIMENTAL
Intervention: Older African Americans with cognitive impairment
Number of subjects: 135
Study 29096697 — intervention group
Group type: COMPARATOR
Intervention: Older Caucasians with cognitive impairment
Number of subjects: 135
Study 29096697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment in African Americans
Number of subjects: 135
Study 29096790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean on-treatment BP (systolic and diastolic)
Number of subjects: 5625
Study 29096803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (Absorb BVS 1.1) implantation
Number of subjects: 36
Study 29096996 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-Tension Glaucoma (NTG) patients
Number of subjects: 13
Study 29096996 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 13
Study 29096996 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG patients
Number of subjects: 13